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individuals treated with retroviral gene therapy. RCR detection
assays are used to detect RCR in manufactured vector, trans-
duced cell products infused into research subjects, and in
the research subjects after treatment. In this study, we re-
viewed 286 control (n = 4) and transduced cell products (n =
282) screened for RCR in the National Gene Vector Bio-
repository. The transduced cell samples were submitted from
14 clinical trials. All vector products were previously shown
to be negative for RCR prior to use in cell transduction. After
transduction, all 282 transduced cell products were negative for
RCR. In addition, 241 of the clinical trial participants were also
screened for RCR by analyzing peripheral blood at least
1 month after infusion, all of which were also negative for evi-
dence of RCR infection. The majority of vector products used
in the clinical trials were generated in the PG13 packaging
cell line. The findings suggest that screening of the retroviral
vector product generated in PG13 cell line may be sufficient
and that further screening of transduced cells does not provide
added value.Received 14 June 2018; accepted 13 August 2018;
https://doi.org/10.1016/j.omtm.2018.08.006.
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The use of genetically modified cells containing retroviral vectors is in
advanced stages of clinical development. Retroviral-based gene ther-
apy for adenosine deaminase deficiency was approved in Europe in
2016.1 The US Food and Drug Administration approved the first
retroviral ex vivo transduced T cell therapy in 2017 for the treatment
of non-Hodgkin’s lymphoma.2Molecular Therapy: Methods & Clinic
This is an open access article under the CC BY-NC-Many retroviral vectors used in clinical applications are based on
murine gammaretroviruses and are designed to be replication
defective (subsequent use of the term retrovirus in this paper
refers to gammaretroviruses). A potential risk of retroviral vectors
is the development of replication-competent retroviruses
(RCRs), which can arise by recombination of viral and cellular
components during vector manufacture.3 Unlike lentiviral vectors,
which have not been shown to generate replication-competent
viruses, retroviral vectors have been associated with RCR develop-
ment. Most commonly, RCRs arose through recombination of
vector and packaging sequences, and decreasing homology be-
tween these sequences has been shown to decrease virus forma-
tion.4–10 Some recombinant retroviruses have also been shown to
contain vector-packaging sequences and cellular-derived genetic
sequeces.11,12
A major concern with RCR infection is treatment-related malig-
nancy. Like the parent murine viruses, RCR generated during
vector production has been shown to cause malignancies in mice
and non-human primates.13,14 Furthermore, retroviral gene therapy
has been associated with leukemia development in a limitedal Development Vol. 10 September 2018 ª 2018 The Author(s). 371
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Schematic Representation of the Extended RCR Assay
The amplification phase allows any existing virus to increase. The presence of RCR
in the culture media is confirmed by introducing cell-free media into the S+/L assay
and analyzing for foci of transformed cells 4–5 days after inoculation.
Molecular Therapy: Methods & Clinical Developmentnumber of clinical trials.15–20While research subjects who developed
vector-associated malignancies did not have evidence of RCR, the
mechanisms of insertional mutagenesis suggest that exposure to
RCR would significantly increase the risk of treatment-related ma-
lignancy. This has influenced recommendations from the US FDA
regarding RCR testing, which has mandated testing at three points.21
First, RCR testing is a required release criterion for retroviral vector
lots used in clinical applications.22 Second, research subjects are to
be monitored at various time points after treatment for the presence
of RCR. The FDA has also imposed a third assessment: RCR testing
must be performed on any cell product cultured ex vivo for more
than 4 days. The number of cells to be tested is 1% of the cell product
or 108 cells, whichever is less.22,23 The rationale for testing an ex vivo
cell product is to detect a low-level RCR that evaded detection in the
vector product.
The similarity between vector and viral particles complicates RCR
detection. As both contain viral proteins such as capsid, integrase,
and reverse transcriptase, protein-detection methods are generally
not helpful. Similarly, assays for reverse transcriptase activity cannot
distinguish RCR from vector particles. While replication-defective
vectors lack the genetic material used in viral replication (i.e., gag,
pol, and env gene regions), the sequences are present in the vec-
tor-producing cells. Carryover of cellular or plasmid DNA into the
vector product will lead to false-positive molecular assays. To date,
culture-based assays provide the highest level of sensitivity for
RCR detection.372 Molecular Therapy: Methods & Clinical Development Vol. 10 SepteAs a recombinant RCR may have a variety of viral and cellular com-
ponents, the growth rate of a given RCR will be unknown at the time
of analysis. Therefore, regulators have required biologic assays to have
a minimum of five passages (approximately 3 weeks) of culture in or-
der to amplify any slow-growing RCR.22 A number of RCR culture
assays have been described.14,24–28 Most combine an amplification
phase allowing a virus to grow to a high titer, followed by a detection
method for viral particles.
While current RCR assays are sensitive, the large number of cells that
must be tested along with the extended period of culture adds signif-
icant cost. Furthermore, it is unknown if screening of ex vivo trans-
duced cells adds additional value when the vector product has been
shown to be RCR negative. Revision in existing RCR testing require-
ments have been called for.29 In this paper, we review the experience
of the National Gene Vector Biorepository (NGVB), an NHLBI-
funded resource (https://www.NGVBCC.org/), which assists investi-
gators in RCR testing of clinical samples. As none of the products
tested to date were found to contain RCR, the experience suggests
re-evaluation of current requirements for testing ex vivo transduced
products.
RESULTS
The RCR assay utilized in this study involves incubating test article
(cells or culture media) with HEK293 cells (Figure 1). This cell line
is highly infectible by retroviral vectors pseudotyped with gibbon
ape leukemia virus (GALV) and RD114 envelopes and amplifies
RCR to high titer.27,28 After the amplification phase, media is then
inoculated into cultures of PG4 cells. The PG4 line is an S+/L line
(sarcoma positive/leukemia negative) cell line, which assumes a trans-
formed phenotype in the presence of murine leukemia viruses
(including RCR).30 If an RCR is present in the test material, foci of
transformed cells are evident in the culture. Any test article with
foci detected in the indicator phase is considered positive for RCR.
Sample Analysis
This analysis reviewed RCR testing of cellular products from 14 clin-
ical trials (Table 1). While the NGVB offers testing for any vector
pseudotype, all the investigators for this study had independently
selected the GALV envelope for their vector. All vectors were gener-
ated in the PG13 cell line,10 except for one study that utilized the
Phoenix-GALV cell line.31 The majority of samples tested were
T cells utilized in cancer immunotherapy trials. Autologous CD34+
hematopoietic progenitor cells and autologous keratinocytes were
also evaluated. All vector products utilized in the clinical trials re-
ported here tested negative for RCR prior to ex vivo transduction of
target cells.
As shown in Table 2, there were 286 samples analyzed in this study.
Four were control samples submitted by investigators (one cell sam-
ple and three supernatants). Of the remaining 282 samples, 266 were
transduced cell samples and a total of 4.53  109 cells were analyzed.
The median number of transduced cells per sample was 1.35 107. In
addition, 16 supernatant test articles were submitted from transducedmber 2018
Table 1. Clinical Trial Samples Evaluated for RCR
IU VPF Study
Number
ClinicalTrial.Gov
Study Number
Principle
Investigator
Initial Assay
Initiated
Final Assay
Completed
Vector Generation
Cell Line Indication
Transduced
Cell Type
10-8 NCT01723306, NCT00664196 Junghans 8/11/10 9/14/10 PG13 CAR-T T cell
11-13 NCT01593696 Mackall 8/13/12 7/30/16 PG13 CAR-T T cell
12-8 NCT00924326 Rosenberg 8/27/12 1/17/17 PG13 CAR-T T cell
13-4 NCT01860937 Curran 10/23/13 9/19/19 PG13 CAR-T T cell
13-7 NCT01044069 Davila 8/22/13 5/10/17 PG13 CAR-T T cell
13-8 NCT01723306 Junghans 5/26/16 7/18/06 PG13 CAR-T T cell
13-32 NCT01263379 Tang 11/4/13 5/10/17 PG13 epidermolysis bullosa keratinocytes
14-4 NCT01593696 Mackall 4/30/14 11/6/16 PG13 CAR-T T cell
14-5 NCT00669669 Kiem 1/14/16 9/16/16 Phoenix-GALV glioblastoma multiforma CD34+
15-9 NCT01723306 Junghans 5/26/16 7/18/16 PG13 CAR-T T cell
15-10 NCT02215967 Kochenderfer 10/26/15 1/21/16 PG13 CAR-T T cell
15-14 NCT02664363 Archer 1/7/16 2/12/16 PG13 CAR-T T cell
15-15 NCT02498912 O’Cearbhaill 12/16/15 11/30/17 PG13 CAR-T T cell
www.moleculartherapy.orgcell cultures. The total volume of media tested was 266mL. All control
and transduced test articles were negative for RCR.
Subject Follow-Up
Of the 282 transduced products analyzed, 271 were infused into 270
subjects (Table 3). The difference between analyzed products and
infused subjects varied. One product was not infused due to a change
in clinical status, and four subjects are awaiting infusion. Seven sub-
jects had both cell and supernatant samples submitted and analyzed
for the same product. One subject had two different products infused.
Of the 270 subjects treated, 241 (89%) had blood tested at least
30 days after infusion for evidence of RCR. The majority of subjects
were evaluated by qPCR analysis using primers and probe for the
GALV envelope (160 of 241, 66%). The remaining subjects were
evaluated by the S+/L assay (without amplification) representing
81 of 241subjects tested (34%). Regardless of testing method, all sub-
jects tested were negative for RCR.
Assay Performance
The performance of the RCR assay was evaluated. As the assay is per-
formed under Good Manufacturing Practice, any variation from the
defined procedure is documented. We found out-of-specification or
deviations in 17 of the 286 samples tested (5.9%). There were five
contaminated samples in the amplification phase that required the
investigator to send additional samples for repeated testing (1.7%).
The 12 remaining tests were completed by repeating the S+/L
portion of the assay using reserve samples from the amplification
phase. The need for repeating the S+/L assays were as follows: six
samples on the same assay required retesting due to a defective
control flask. In five samples, the S+/L assay control did not reach
confluence within the time period required by the standard operating
procedure. There was contamination of one sample in the S+/L
assay.Molecular TheThe assay sensitivity is 1 focus forming unit of RCR per 1 mL test
article media incubated with R2  105 HEK293 cells or one test
article cell co-cultured withR5 HEK293 cells. The ratio of test article
to HEK293 cells was established to minimize receptor interference
between vector and RCR; all assays reported were reviewed and
met the appropriate ratio.DISCUSSION
An important safety concern for patients seeking retroviral gene
therapy is exposure to RCR. In this manuscript, we report a multi-
institutional study including samples from 10 research groups
involved with 14 clinical trials. No evidence of RCR was found in
282 transduced cell products tested in a rigorous RCR assay. Also,
there was no evidence of RCR in the 241 research subjects screened
for RCR post-treatment.
The NGVB recently reported on the lack of replication-competent
lentivirus (RCL) in ex vivo transduced T cells used in cancer immu-
notherapy trials.32 In that study, 460 cell products were tested with
no evidence of RCL. Although the potential risk of RCR is likely
higher than that of current third-generation lentiviral vectors, our
current study provides additional support for the safety of retroviral
vectors. RCL has not been reported with current HIV-1-based sys-
tems, and this finding likely relates to deletion of HIV-1 accessory
genes, use of self-inactivating long terminal repeats (LTRs), the sepa-
ration of packaging sequences on to different plasmids, and the use of
transient transfection production methods that limit the time for vec-
tor generation to less than 1 week.33 While methods for transient
transduction of retroviral vectors are well described,34 many retro-
viral vectors are generated in packaging cell lines, which require clone
selection, expansion for master cell bank generation, and expansion
for vector production, a process that typically takes weeks to months
during which time recombinations could occur. Furthermore,rapy: Methods & Clinical Development Vol. 10 September 2018 373
Table 2. Number and Size of RCR Samples Analyzed by Study
NGVB
Study
Number
Principle
Investigator
All Cell
Samples
Negative
Control
Samples
Transduced
Samples
Total
Number
of Control
Cells
Tested
Total
Number of
Transduced
Cells Tested
Mean
Number of
Transduced
Cells per
Assay
Ratio of
Test Cell
to HEK293
Cell
Supernatant
Samples
Assayed
Negative
Control
Samples
Transduced
Supernatant
Samples
Total
Volume of
Negative
Control
Samples
(mL)
Total
Volume of
Transduced
Test Article
(mL)
Mean
Volume of
Transduced
Test Article
(mL)
Ratio of
Test Volume
(mL) to 105
HEK293
Cell
10-8 Junghans 12 0 12 0 1.28E+07 1.07E+06 6.2
11-13 Mackall 53 0 53 0 4.86E+08 9.16E+06 6.0
12-8 Rosenberg 91 0 91 0 1.12E+09 1.23E+07 5.6
13-4 Curran 24 0 24 0 9.20E+08 3.80E+07 5.3 2 0 2 0 173 86.5 2.3
13-7 Davila 39 0 39 0 1.51E+09 3.88E+07 5.3
13-8 Junghans 1 0 1 0 1.00E+06 1.00E+06 5.0
13-32 Tang 7 0 7 0 1.40E+07 2.00E+06 8.6 7 0 7 0 34 4.9 8.2
14-4 Mackall 13 0 13 0 1.22E+08 9.38E+06 6.1
14-5 Kiem 4 0 4 0 45 11.5 4.4
15-9 Junghans 7 0 7 0 7.00E+06 1.00E+06 5.0
15-10 Kochenderfer 10 0 10 0 1.40E+08 1.40E+07 5.4
15-14 Archer 6 3 3 13 14 4.7 8.5
15-15 O’Cearbhaill 10 1 9 1.05E+07 2.01E+08 2.23E+07 5.4
Total 267 1 266 1.05E+07 4.53E+09 19 3 16 13 266
Mean 1.35E+07 5.8 26.9 5.9
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Table 3. Follow-Up Testing for RCR by Study Infused with Transduced Cell Products
IU VPF Study
Number
Principle
Investigator
Number of
Products Infused
Number of
Subjects Infused
Subjects with
RCR Follow-up
Method of RCR
Detection Level of Sensitivity per DNA
10-8 Junghans 12 12 5 qPCR <10 copies/0.2 mcg DNA
11-13 Mackall 53 53 53 qPCR <10 copies/0.2 mcg DNA
12-8 Rosenberg 91 90 80 S+/L 1 FFU/mL
13-4 Curran 26 26 26 qPCR <10 copies/0.2 mcg DNA
13-7 Davila 39 39 39 qPCR <10 copies/0.2 mcg DNA
13-8 Junghans 1 1 1 qPCR <10 copies/0.2 mcg DNA
13-32 Tang 7 7 7 qPCR <10 copies/0.2 mcg DNA
14-4 Mackall 12 12 10 qPCR <10 copies/0.2 mcg DNA
14-5 Kiem 4 4 4 qPCR <10 copies/0.2 mcg DNA
15-9 Junghans 7 7 2 qPCR and S+/L <10 copies/0.2 mcg DNA, 1 FFU/mL
15-10 Kochenderfer 10 10 9 qPCR <10 copies/0.2 mcg DNA
15-14 Archer 0 0 0 N/A N/A
15-15 O’Cearbhaill 9 9 5 qPCR <10 copies/0.2 mcg DNA
Total 271 270 241
FFU, focus forming unit; mcg, microgram.
www.moleculartherapy.orgretroviral vector systems generally retain most of the components
needed to generate a gammaretrovirus including the wild-type LTR.
The selection of the retroviral packaging cell line is an important
factor in the risk of RCR development. A variety of packaging
cell lines were developed in the 1980s and 1990s, and RCR was re-
ported.4–8,11,12 Subsequent modification in packaging cell lines appear
to decrease the chance of recombination and PG13 cells appears to be
the preferred cell line for many investigators.10 One advantage of the
PG13 cell line is that it was generated in NIH 3T3 cells, a murine-
derived cell line. The GALV envelope used in PG13 cell lines is a fe-
line-derived virus, and the receptor for the envelope is not present on
murine cells. If an RCR did develop in a PG13 cell, the virus would not
be expected to propagate within the culture.
Whether the finding of RCR free vector with the PG13 cell line applies
to other methods and cell lines will depend on characteristics of the
vector and cell line. Additional testing will require study before the
safety data noted here can be extrapolated to other systems. One of
the products included in this study utilized the Phoenix-GALV pack-
aging cell line, which is based on the human HEK293 cell line. While
the experience here is limited, it generated vector that was RCR free in
the vector product, in transduced CD34+ cells, and in research
subjects.
The US FDA requires subjects treated with retroviral products to be
monitored for RCR post-infusion. Currently, there is no guidance
requiring a specific assay, and the majority of investigators chose a
qPCR-based assay for the viral envelope, predicting that any
RCR would contain the GALV envelope. One investigator chose the
S+/L assay (without HEK293 amplification). All samples testedMolecular Thewere negative providing further support for the safety of current
retroviral packaging systems.
While all NGVB investigators within the RCR study time frame were
invited to participate in this study, four did not provide data on pa-
tient follow-up and the 93 RCR assays performed for their trials
were not included in this analysis. While we excluded these samples
due to lack of follow-up, the cell products tested in the NGVB were
all negative for RCR.
In summary, RCR has not been detected in cell products manufac-
tured for clinical use. Participants evaluated post-infusion were also
without evidence of RCR exposure. It should be noted all but one
study utilized the PG13 cell line. Given the known development of
RCR in other cell lines and envelopes, additional studies would be
required before extending these findings to other packaging cell lines.
Given this caveat, screening cell products for RCR does not add addi-
tional assurance of safety and should no longer be required when a
well-characterized cell line and the resulting retroviral vector product
have been successfully screened for RCR.
MATERIALS AND METHODS
Collection of Study Data
The NGVB is an NIH-sponsored resource that assists gene-therapy
investigators in meeting FDA-required testing (https://www.
NGVBCC.org/). Only samples intended for in vivo administration
were included in the analysis. Investigators with study agreements
agreeing to participate were sent a list of their test articles with the
dates of assay initiation and completion. Participants were asked to
supply the following information: (1) production method (stable
packaging cell line versus transient transduction); (2) enveloperapy: Methods & Clinical Development Vol. 10 September 2018 375
Table 4. Passage Methodology and Ratio of Test Article to HEK293 Cells
Test Supernatant Volume HEK293 Cells Flask Size Split 1 Split 2 SplitR 3
1–4 mL 2  106 25 cm2 1:5 25 cm2 1:5 25 cm2 1:5 25 cm2
10–15 mL 5  106 75 cm2 1:5 75 cm2 1:5 75 cm2 1:5 75 cm2
30–50 mL 1.5  107 175 cm2 1:10 75 cm2 1:5 75 cm2 1:5 75 cm2
60–90 mL 2  107 300 cm2 1:10 175 cm2 1:10 175 cm2 1:5 75 cm2
90–120 mL 3  107 450 cm2 1:10 175 cm2 1:10 175 cm2 1:5 75 cm2
Test Cell Number HEK293 Cells Flask Size Split 1 Split 2 SplitR 3
2 to 4  105 2  106 25 cm2 1:5 25 cm2 1:5 25 cm2 1:5 25 cm2
5 to 10  105 5  106 75 cm2 1:5 75 cm2 1:5 75 cm2 1:5 75 cm2
1.5 to 3  106 1.5  107 175 cm2 1:10 75 cm2 1:5 75 cm2 1:5 75 cm2
2 to 4  106 2  107 300 cm2 1:10 175 cm2 1:10 175 cm2 1:5 75 cm2
3 to 6  106 3  107 450 cm2 1:10 175 cm2 1:10 175 cm2 1:5 75 cm2
Molecular Therapy: Methods & Clinical Developmentpseudotype; (3) clinical indication; (4) clinicaltrial.gov identifier; (5) if
the product was administered to the subject; (6) if the clinical vector
product was shown to be RCR free prior to use in the clinical trial; (7)
the results of post-infusion RCR screening (if performed R30 days
infusion); and (8) the method of post-infusion testing and the level
of sensitivity of the assay. For research subjects screened for RCR after
product administration, the site and method of screening was at the
investigators’ discretion.
Cell Line and Positive Control Preparation
HEK293 (American Type Culture Collection [ATCC], Manassas, VA;
catalog CRL-1573) and Mink GALV SEATO cells (a kind gift of M.
Eiden and C. Wilson, NIH, Bethesda, MD) were maintained in
D10 medium (DMEM; Invitrogen, Carlsbad, CA) with 10% fetal
bovine serum (FBS; Hyclone, Logan, UT), 2 mM L-glutamine (Invi-
trogen), 1 mM sodium pyruvate, and 100 units/mL penicillin and
100 mg/mL streptomycin (Invitrogen). PG4 cells (ATCC, CRL-
2032) were maintained in MyCoys 5A media with 10% FBS and
100 units/mL penicillin and 100 mg/mL streptomycin. All cell lines
were maintained at 37C and 5% CO2.
The positive control for the assay utilizes the GALV SEATO virus.
The NGVB maintains this cell bank, and a vial of cells are thawed,
placed in a 75-cm2 flask, and expanded over three passages into three
175-cm2 flasks. After three passages, media is changed on confluent
flasks and media is harvested after approximately 24 hr and filtered
through a 0.45-mm filter. The media is aliquoted into cryovials, and
the virus stock is stored at % –70C for no more than 5 years. The
tissue culture infective dose 50 (TCID50) of the virus stock is deter-
mined on PG4 cells.
RCR Assays
Amplification Phase
HEK293 cells are expanded to the number required based on the test
articles to be assayed. On day1, assay control flasks are prepared by
plating eight 25-cm2 flasks with 2 106 HEK293 cells per flask; three
flasks will be used for negative control and five flasks will be used for376 Molecular Therapy: Methods & Clinical Development Vol. 10 Septethe positive control. For liquid test articles, HEK293 cells are plated in
flasks of different sizes to attain a test-volume-to-HEK293-cell ratio
within a specified range (Table 4). Similarly, cell test articles are plated
at specific test-cell-to-HEK293-cell ratio, also shown in Table 4.
On day 0, medium is removed from the supernatant test article and
control flasks and control and test articles are added. For the negative
control, 1 mL of D10 medium is added. For the positive control,
GALV SEATO virus at the TCID50 (in 1 mL of media) is added to
five 25-cm2 flasks. Test articles are added to the appropriate flasks
at specified ratios according to Table 4. Polybrene at a final concen-
tration of 8 mg/mL is added to all controls and supernatant test
articles. Cultures are then incubated for 2–4 hr, after which time
medium is removed from control and supernatant flask, fresh
medium is added, and cultures are returned to the incubator. Cells
are split at a 1:5 ratio, decreasing the size of flasks at split 1 as shown
in Table 4.
Cultures are maintained in log-phase growth, passaging a minimum
of five times over a 3-week period. At the end of this period, a media
change is performed when cells are confluent and the media is
collected 24 hr after the exchange. The media is filtered through a
0.45-mm filter and either used immediately or frozen at 70C to
80C for later testing. Reserve samples are also stored at 70C to
80C in case repeat testing is required.
Indicator Phase
On days 14–15 of the amplification phase, a vial of PG4 cells are
thawed and expanded. On day 1 of the assay, cells are plated in
6-well dishes with 4 mL of media and 1  105 cells per well. On
day 0, the media is removed from the wells. There are two sets of con-
trols. The “amplified” negative and positive controls are set up using
the respective media from the corresponding amplification-phase
negative and positive controls. 1 mL from the respective negative
control cultures are filtered (0.45 mm) and added to two wells of
PG4 undiluted. These control for adequate amplification of virus dur-
ing the 3 weeks of culture.mber 2018
www.moleculartherapy.orgIn addition, a new set of “direct” negative controls and “direct” pos-
itive controls are evaluated using diluted GALV SEATO virus. 1mL of
media is added to three “direct” negative control wells. The “direct”
positive control consists of GALV SEATO virus that is of a known
potency and is plated at five serial log dilutions, with at least two di-
lutions below the TCID50.
For each test article culture, three wells are evaluated, two wells
containing 1 mL of undiluted amplification phase media and one
well containing 1 mL of amplification media diluted 1:100. Polybrene
at a final concentration of 8 mg/mL is added to all control and test
articles.
Cultures are incubated from 2 to 4 hr, and the media is removed and
replaced with 4 mL of media. On day 2, the medium is removed from
each well and replaced. On day 4, wells are inspected for foci using an
inverted microscope (if wells are not confluent they are re-fed and
read on days 5–6). The foci are enumerated independently by two
technicians. The PG4 assay is acceptable if the following three criteria
are met: (1) no foci are observed in the negative control wells; (2) foci
are noted at a dilution which is 2-log more concentrated than the
TCID50 dilution in the direct positive control; and (3) one or more
wells of the five amplification-positive controls originally inoculated
at the TCID50 contain foci. A test article is considered positive for
RCR if one or more foci are detected.AUTHOR CONTRIBUTIONS
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